We are live on ! Find out more
Daiwa Securities Group

Daiwa Securities Group Portfolio holdings

AUM $34.8B
1-Year Est. Return 20.7%
This Fund
S&P 500
This Quarter Est. Return
+6.5%
1 Year Est. Return
+20.7%
3 Year Est. Return
+66.64%
5 Year Est. Return
+79.21%
10 Year Est. Return
+192.59%
AUM
$11.8B
AUM Growth
+$485M
Cap. Flow
-$250M
Cap. Flow %
-2.12%
Top 10 Hldgs %
39.85%
Holding
1,230
New
34
Increased
603
Reduced
253
Closed
43

Sector Composition

Rank Sector Weight
1 Real Estate 73.1%
2 Technology 4.03%
3 Financials 3.16%
4 Industrials 2.98%
5 Healthcare 2.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ATRA icon
1051
Atara Biotherapeutics
ATRA
$71.2M
$5K ﹤0.01%
14
+2
+17% +$746
OMER icon
1052
Omeros
OMER
$790M
$5K ﹤0.01%
309
PACB icon
1053
Pacific Biosciences
PACB
$426M
$5K ﹤0.01%
960
RYTM icon
1054
Rhythm Pharmaceuticals
RYTM
$7.26B
$5K ﹤0.01%
219
QTTB icon
1055
Q32 Bio
QTTB
$467M
$5K ﹤0.01%
16
+3
+23% +$1.02K
TVRD
1056
Tvardi Therapeutics
TVRD
$23.3M
$5K ﹤0.01%
8
+1
+14% +$831
EGRX
1057
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$5K ﹤0.01%
82
GTHX
1058
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$5K ﹤0.01%
238
NSTG
1059
DELISTED
NanoString Technologies, Inc.
NSTG
$5K ﹤0.01%
226
+30
+15% +$796
ENDP
1060
DELISTED
Endo International plc
ENDP
$5K ﹤0.01%
1,427
ARQL
1061
DELISTED
Arqule Inc
ARQL
$5K ﹤0.01%
712
DOVA
1062
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$5K ﹤0.01%
183
+41
+29% +$664
CERS icon
1063
Cerus
CERS
$611M
$4K ﹤0.01%
871
CYTK icon
1064
Cytokinetics
CYTK
$10.9B
$4K ﹤0.01%
363
HCM icon
1065
HUTCHMED
HCM
$1.91B
$4K ﹤0.01%
215
KPTI icon
1066
Karyopharm Therapeutics
KPTI
$172M
$4K ﹤0.01%
26
KURA icon
1067
Kura Oncology
KURA
$930M
$4K ﹤0.01%
288
+46
+19% +$819
MGNX icon
1068
MacroGenics
MGNX
$250M
$4K ﹤0.01%
310
NTLA icon
1069
Intellia Therapeutics
NTLA
$1.52B
$4K ﹤0.01%
288
QTRX icon
1070
Quanterix
QTRX
$176M
$4K ﹤0.01%
178
+37
+26% +$1.03K
RCKT icon
1071
Rocket Pharmaceuticals
RCKT
$355M
$4K ﹤0.01%
321
+45
+16% +$558
VNDA icon
1072
Vanda Pharmaceuticals
VNDA
$316M
$4K ﹤0.01%
335
VYGR icon
1073
Voyager Therapeutics
VYGR
$189M
$4K ﹤0.01%
232
WVE icon
1074
Wave Life Sciences
WVE
$1.15B
$4K ﹤0.01%
213
RVNC
1075
DELISTED
Revance Therapeutics, Inc.
RVNC
$4K ﹤0.01%
280

Similar funds

Daiwa Securities Group's Q3 2019 Portfolio in Review

As of Q3 2019, Daiwa Securities Group held 1,230 positions worth $11.8B, up 4.3% from $11.3B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Daiwa Securities Group's Q3 2019 filing shows 34 new, 603 increased, 253 reduced and 43 closed positions. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 42,579 shares worth $12.6M. The largest sale was Public Storage, an estimated $190M.

By sector, the portfolio is most concentrated in Real Estate at 73% of assets, up from 72% a quarter earlier, followed by Technology and Financials.

  • Daiwa Securities Group's largest Q3 2019 buy was State Street SPDR S&P 500 ETF Trust: 42,579 shares worth $12.6M.
  • Daiwa Securities Group added most to Realty Income in Q3 2019, an estimated $211M increase.
  • Daiwa Securities Group's biggest Q3 2019 reduction was Public Storage, cutting an estimated $190M.
  • Daiwa Securities Group fully exited Coupa Software Incorporated in Q3 2019, selling an estimated $4.17M.
  • Daiwa Securities Group's ten largest holdings make up 40% of its $11.8B portfolio in Q3 2019.
  • Daiwa Securities Group opened 34 new positions and closed 43 in Q3 2019.
  • Daiwa Securities Group's portfolio value rose 4.3% quarter-over-quarter to $11.8B.

Based on Daiwa Securities Group's 13F filing for Q3 2019, filed 4 Nov 2019.